Christopher Frankenfield
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2023-08-03–present
-
Xilio Therapeutics, Inc. (XLO)
Proxy statement
Current
Company network
Recorded roles and earnings-call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Xilio Therapeutics, Inc. (XLO) | Chief Financial and Operating Officer | $533,100 | $3,229,346 |
| 2024 | Xilio Therapeutics, Inc. (XLO) | Chief Financial and Operating Officer | $506,135 | $1,035,971 |
Recent activity
No earnings-call appearances or filed executive changes recorded yet.